{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=42", "query": { "intervention": "Random Match", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 5394, "total_pages": 540, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T00:15:41.104Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01179737", "title": "Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" }, { "name": "Placebo to nilotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2010-07", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01179737" }, { "nct_id": "NCT01143246", "title": "A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatorenal Syndrome" ], "interventions": [ { "name": "Terlipressin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2010-10-11", "completion_date": "2013-05-10", "has_results": true, "last_update_posted_date": "2022-11-29", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143246" }, { "nct_id": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Placebo for Olaparib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nab-paclitaxel+carboplatin", "type": "DRUG" }, { "name": "Gemcitabine+carboplatin", "type": "DRUG" }, { "name": "Pemetrexed+carboplatin", "type": "DRUG" }, { "name": "Gemcitabine+cisplatin", "type": "DRUG" }, { "name": "Pemetrexed+cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 401, "start_date": "2018-12-21", "completion_date": "2026-09-27", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 9, "location_summary": "Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more", "locations": [ { "city": "Bonita Springs", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775486" }, { "nct_id": "NCT02847702", "title": "A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis Pain of the Knee" ], "interventions": [ { "name": "VM902A 200-mg Capsules", "type": "DRUG" }, { "name": "VM902A 400-mg Capsules", "type": "DRUG" }, { "name": "Naproxen 500-mg Capsules", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Purdue Pharma LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 75, "start_date": "2016-08", "completion_date": "2016-11-22", "has_results": false, "last_update_posted_date": "2017-11-22", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • DeLand, Florida + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "DeLand", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Homestead", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02847702" }, { "nct_id": "NCT02038647", "title": "Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2014-05-12", "completion_date": "2017-07-10", "has_results": true, "last_update_posted_date": "2018-12-27", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 21, "location_summary": "Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038647" }, { "nct_id": "NCT00621855", "title": "RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Disease" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "dabigatran etexilate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1878, "start_date": "2008-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-03-12", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 1, "location_summary": "Clearwater, Florida", "locations": [ { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00621855" }, { "nct_id": "NCT07662148", "title": "A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "BIIB144", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2026-07-21", "completion_date": "2028-06-19", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT07662148" }, { "nct_id": "NCT04971785", "title": "Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Semaglutide (SEMA)", "type": "DRUG" }, { "name": "Cilofexor (CILO)/Firsocostat (FIR)", "type": "DRUG" }, { "name": "PTM SEMA", "type": "DRUG" }, { "name": "PTM CILO/FIR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 457, "start_date": "2021-08-09", "completion_date": "2024-12-09", "has_results": true, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 175, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971785" }, { "nct_id": "NCT00371748", "title": "A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "TAXUS Liberté-SR", "type": "DEVICE" }, { "name": "TAXUS™ Express2", "type": "DEVICE" }, { "name": "Express2", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 261, "start_date": "2005-02", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2012-02-02", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 19, "location_summary": "Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00371748" }, { "nct_id": "NCT00286455", "title": "Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Alogliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 329, "start_date": "2006-02", "completion_date": "2007-07", "has_results": true, "last_update_posted_date": "2012-02-03", "last_synced_at": "2026-10-28T00:15:41.104Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Artesia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00286455" } ] }